Don’t miss – Page 14 – Endpoints News

SUBSCRIBE

#JPM19 starts with Eli Lilly's $8B buyout of Loxo Oncology — so who's next?

7 months ago

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

7 months ago

How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples

7 months ago

Juno founders set their sights on creating an ‘epic’ new biotech with high-rolling investors at their back

7 months ago

Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?

7 months ago

The Atlas 5 raise a $250M 'opportunity fund' for later-stage biotech investing

7 months ago

The year of living large: A fledgling Relay Therapeutics reaps a whopping $400M venture round, with SoftBank pointing the way to a windfall

8 months ago

Novartis CAR-T chief drops out of Big Pharma, joins the great migration to a favorite biotech destination

8 months ago

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

8 months ago

This is the FDA’s year to shine, but can biopharma keep up as regulators continue to rev up chart-topping numbers?

8 months ago

A new analysis spotlights the top 20 drugs in the late-stage pipeline

8 months ago

'Idea Man' Paul Allen leaves behind plan to unscramble human immunology

8 months ago

Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune

8 months ago

Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company

8 months ago

Nasdaq celebrates epic biotech IPO success in 2018. But can the party on Wall Street rumba on?

8 months ago

Moderna skirts the reefs of disaster and sails into Wall Street with a $604M IPO bounty — but shares slide

8 months ago

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

8 months ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

8 months ago

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18's biggest ever datapalooza

8 months ago

#ASH18: Can Amgen break through the BCMA CAR-T line and take a BiTE of the multiple myeloma market? It won't be quick or easy

8 months ago

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

8 months ago

#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will bluebird say?

8 months ago

#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than the rest

8 months ago

#ASH18: Bluebird and Celgene didn’t 'break' their next-gen BCMA CAR-T, so now they’ll double down on the dose and root for real durability

8 months ago

First page Previous page 11 12 131415 Next page Last page